Sentence examples for development trials for from inspiring English sources
It should be noted that this may also reflect a lack of systematic tissue collection and translational research in the drug development trials for this disease.
Following 3 presentations, Dr. Feng Roger Luo from Janssen Pharmaceutical R&D and USCACA overviewed the essential goals of early clinical development trials for molecularly targeted agents and the principal of pharmacological audit trail, and then discussed 3 presentations and remarked on these 3 new agents by using the key evaluation criteria for phase I or I/IIa trial.
Our plea for a strong commitment of all involved parties (academia, pharmaceutical industry, independent funding sources, and advocacy groups) to develop well-designed, high-quality multidisciplinary (involving other issues than drug-development) trials for ABC remains of critical importance.
Multi-dimensional image analysis is being used increasingly to arrive at surrogate end-points for drug development trials.
The medical image analysis community is moving towards advanced software systems specifically designed for drug development trials.
There are two types of clinical trials which intervene with the clinical care of patients: development trials undertaken by pharmaceutical companies for the purpose of drug licensing approval, and post-approval studies mostly led by physicians/investigators.
Although semiquantitative measures usually suffice in the clinic, it may be that the use of dynamic scanning with kinetic analysis is more appropriate for drug development trials and may provide a more accurate assessment of changes in tumour metabolism.
In order to improve efficiency and reduce the cost of development, future trials for new targeted agents in NSCLC should aim to recruit patients on the basis of tumour biology rather than clinical characteristics.
At present, most systems exist only as small-scale pilot studies, and there is a pressing need for governments to provide targeted research and development funding and strong incentives for large-scale development, trialling and implementation of interventions, and for policymakers and healthcare professionals to integrate solutions into existing care models across the globe.
The objective is not to second-guess past efforts but to place the lessons in perspective to allow for trial success in the future to improve agent development, trial design, and ultimately, clinical outcomes for new therapeutics for PAD.
